Axovant Sciences has announced an equity offering to raise $100m in gross proceeds, along with a 30-day option to underwriters to purchase up to an additional $15m worth of its common stock shares.
The proceeds are intended to be used for the clinical development of the company’s product candidates, intepirdine, nelotanserin, RVT-103 and RVT-104, as well as to supplement the company’s working capital and for general corporate purposes.
Axovant Sciences is a clinical-stage biopharmaceutical company based in Bermuda.
Swiss biopharmaceutical company Ferring International Center has entered a development agreement with German drug delivery company ALRISE Biosystems.
The agreement gives the former company exclusive option rights to leverage the latter’s ImSus technology platform.
The companies intend to develop an injectable, controlled-release formulation of a peptide therapeutic through the agreement.
The German company will conduct feasibility and scale-up studies with Ferring International, while the latter will have the right to exercise its option and enter a definitive agreement with the former to further develop and manufacture the formulation.
Japanese pharmaceutical company Takeda Pharmaceutical Company and US-based biological products maker Nubiyota have entered an agreement to advance oral microbial consortia products developed by the latter’s microbiome platform for gastrointestinal indications with a high unmet medical need.
NuBiyota will receive an upfront payment as part of the agreement, and is also eligible to receive development, regulatory and commercial milestones and tiered royalties based on net sales of the products.
Cynata Therapeutics and Critical Care Research Group (CCRG) have partnered to investigate the former's Cymerus mesenchymal stem cells in treating acute respiratory distress syndrome with extracorporeal membrane oxygenation.
The Prince Charles Hospital and Brisbane’s Critical Care Research Group will evaluate the stem cells.
Based in Australia, Cynata Therapeutics is a stem-cell and regenerative medicine company, whereas CCRG is a research institute.
Swedish biotechnology company Genovis intends to raise Skr11.5m ($1.26m) in gross proceeds through a rights offering of five million shares of its common stock.
The company intends to use the proceeds in order to expand product offerings.